All In Biotech

Drug Trial Radar · NCT05055908

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy

Last checked: Nov 20, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

12,000

Planned (sponsor's estimate)

Start

Oct 1, 2021

Primary completion

Jul 1, 2025

Study completion Sep 14, 2027

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.

Conditions

  • Lung Cancer

Interventions

  • Pemetrexed plus PembrolizumabDrug

    Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days

  • PembrolizumabDrug

    Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.

  • PemetrexedDrug

    Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlation between Adverse events (AEs) and gene profileTime frame: Time from first subject dose to study completion, or up to 36 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.